Seqens Seqens

X
[{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TargEDys and Inoliva Announce They Have Entered a Distribution Partnership to Bring Satylia\u00ae to Turkey","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by TargEDys

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Satylia, also called EnteroSatys in other markets, is a precision probiotic with a characterized mechanism of action at molecular level: it increases feelings of fullness thanks to the probiotic's protein ClpB that mimics the satiety hormone alpha-MSH.

            Lead Product(s): Undisclosed

            Therapeutic Area: Nutrition and Weight Loss Product Name: Satylia

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Inoliva

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY